Skip to main content
. 2020 Dec 10;11:589654. doi: 10.3389/fimmu.2020.589654

Figure 1.

Figure 1

Schematic illustrations showing the approaches of controlling signal transduction of IL-1β. 1. Anakinra can competitively bind with IL-1R1 against IL-1β or IL-1α; 2. The Fab segment of canakinumab overlapped the D1 region of IL-1R1 when canakinumab bind to IL-1β, so that IL-1 βcould not bind to IL-1R1; 3. gevokizumab occupies the allosteric site of IL-1 and reduces the affinity of the complex to IL-1Racp and IL-1R1; 4. IL-1-C-Qβ(vaccine) produces polyclonal antibodies to neutralize IL-1; 5. Extracellular regions of IL-1R1 and IL-1Racp form rilonacept’s two arms that could trap IL-1. IL-1R, IL-1 receptor; TIR, the Toll-and IL-1R-like domains; VLP, virus like particles; IL-1R1, type II L-1R; IL-1 Racp, IL-1R accessory protein.